Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer E Ho

Showing results (1-10 of 253) with videos related to

Pageof 26
Sort By:
Circulation. Cardiovascular Genetics|December 15, 2017
Harnessing the Power of Pharmacometabolomics: The Metabolic Footprint of StatinsJennifer E Ho
Journal of the American Heart Association|September 10, 2020
Aldosterone Antagonism in Atrial Fibrillation: Implications for AF-Predominant HFpEFJennifer E Ho
Evaluation and Program Planning|January 23, 2022
What counts? The critical role of qualitative data in teachers' decision makingJennifer E Ho
Journal of the American College of Cardiology|July 29, 2017
High-Sensitivity Troponin in the General Population: Time for a New Normal?Jennifer E Ho
The Canadian Journal of Cardiology|July 24, 2018
β-Blockers After Inotropes in Acute Heart Failure-When Is the Right Time?Jennifer E Ho
JACC. Heart Failure|May 15, 2017
Can Heart Failure With Preserved Ejection Fraction Shed Light on the Mortality-Readmissions Paradox?Jennifer E Ho
Journal of the American College of Cardiology|May 8, 2010
B-type natriuretic peptide testing in the general population: are we ready for prime time?Jennifer E Ho, Daniel Levy
Current Atherosclerosis Reports|August 7, 2002
Postmenopausal hormone replacement therapy and atherosclerosisJennifer E Ho, Lori Mosca
JACC. Heart Failure|February 10, 2024
Subclinical Atrial Fibrillation in HFpEF: Malicious Accomplice or Innocent Bystander?Jennifer E Ho, Prashanthan Sanders
Journal of the American College of Cardiology|April 13, 2019
Reply: Galectin-3: A Pathophysiological Background Index or an Emerging Prognostic Biomarker in Heart Failure?Anahita Ghorbani, Jennifer E Ho
Pageof 26

Showing results (1-10 of 253) with videos related to

Sort By:
Pageof 26
Circulation. Cardiovascular Genetics|December 15, 2017
Harnessing the Power of Pharmacometabolomics: The Metabolic Footprint of StatinsJennifer E Ho
Journal of the American Heart Association|September 10, 2020
Aldosterone Antagonism in Atrial Fibrillation: Implications for AF-Predominant HFpEFJennifer E Ho
Evaluation and Program Planning|January 23, 2022
What counts? The critical role of qualitative data in teachers' decision makingJennifer E Ho
Journal of the American College of Cardiology|July 29, 2017
High-Sensitivity Troponin in the General Population: Time for a New Normal?Jennifer E Ho
The Canadian Journal of Cardiology|July 24, 2018
β-Blockers After Inotropes in Acute Heart Failure-When Is the Right Time?Jennifer E Ho
JACC. Heart Failure|May 15, 2017
Can Heart Failure With Preserved Ejection Fraction Shed Light on the Mortality-Readmissions Paradox?Jennifer E Ho
Journal of the American College of Cardiology|May 8, 2010
B-type natriuretic peptide testing in the general population: are we ready for prime time?Jennifer E Ho, Daniel Levy
Current Atherosclerosis Reports|August 7, 2002
Postmenopausal hormone replacement therapy and atherosclerosisJennifer E Ho, Lori Mosca
JACC. Heart Failure|February 10, 2024
Subclinical Atrial Fibrillation in HFpEF: Malicious Accomplice or Innocent Bystander?Jennifer E Ho, Prashanthan Sanders
Journal of the American College of Cardiology|April 13, 2019
Reply: Galectin-3: A Pathophysiological Background Index or an Emerging Prognostic Biomarker in Heart Failure?Anahita Ghorbani, Jennifer E Ho
Pageof 26